Drugs / GSK1322888
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01294566 | Nov 2010 → Mar 2011 | gastroparesis | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK1322888 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01294566 ↗ |
| Action | Activate | “motilin receptor agonist” NCT01294566 ↗ |
| Modality | Small molecule | “GSK1322888 is a potent and selective small molecule motilin receptor agonist” NCT01294566 ↗ |
| Route | Oral | “Single Oral Doses of GSK1322888” NCT01294566 ↗ |